Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment

• Published in: BMC cardiovascular disorders Vol. 21; no. 1; p. 214
• Main Authors: Zhang, Rong-Feng, Ma, Cheng-Ming, Wang, Na, Yang, Ming-Hui, Li, Wen-Wen, Yin, Xiao-Meng, Dong, Ying-Xue, Yu, Xiao-Hong, Xiao, Xian-Jie, Xia, Yun-Long, Gao, Lian-Jun
• Format: Journal Article
• Language: English
• Published: England BioMed Central 27.04.2021; BMC
• Subjects: Ablation; Administration, Oral; Aged; Anticoagulants; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Atrial fibrillation; Atrial Fibrillation - complications; Atrial Fibrillation - diagnosis; Atrial Fibrillation - surgery; Bleeding; Blood transfusions; Cardiac arrhythmia; Catheter Ablation - adverse effects; Catheters; China; Clinical trials; Clotting; Dabigatran - administration & dosage; Dabigatran - adverse effects; Dosage; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Embolisms; Female; Fibrillation; Heart surgery; Heparin; Heparin - administration & dosage; Heparin - adverse effects; Humans; Male; Middle Aged; New oral anticoagulants; Patients; Postoperative Hemorrhage - chemically induced; Prospective Studies; Radiofrequency ablation; Radiofrequency catheter ablation; Risk Assessment; Risk Factors; Rivaroxaban - administration & dosage; Rivaroxaban - adverse effects; Stroke; Stroke - diagnosis; Stroke - etiology; Stroke - prevention & control; Thromboembolism; Thromboembolism - diagnosis; Thromboembolism - etiology; Thromboembolism - prevention & control; Time Factors; Treatment Outcome; Veins & arteries; Warfarin; Warfarin - administration & dosage; Warfarin - adverse effects; Whole Blood Coagulation Time; China; United States > US; Radiofrequency catheter ablation; Atrial fibrillation; New oral anticoagulants; Bleeding

To clarify the appropriate initial dosage of heparin during radiofrequency catheter ablation (RFCA) in patients with atrial fibrillation (AF) receiving uninterrupted nonvitamin K antagonist oral anticoagulant (NOAC) treatment. A total of 187 consecutive AF patients who underwent their first RFCA in...